Fed. Circ. Clips Exela Appeal In Ofirmev Infringement Row
By Vin Gurrieri ( March 23, 2015, 5:28 PM EDT) -- The Federal Circuit on Monday upheld a Delaware federal judge's ruling that Exela Pharma Sciences LLC and two related entities flouted two Cadence Pharmaceuticals Inc. patents covering the injectable pain reliever Ofirmev by planning a generic version of the drug....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.